

## ACYP2 (B-3): sc-398298



The Power to Question

## BACKGROUND

The formation of stable highly organized protein aggregates, known as amyloid fibrils, is associated with several debilitating human diseases, including Alzheimer's disease, Parkinson's disease, and Creutzfeldt-Jakob disease. In each of these conditions, a peptide or protein that is normally soluble accumulates into insoluble fibrils. Muscle acylphosphatase (AcP) has emerged as a significant model system to study protein misfolding and aggregation. It is particularly suitable for these studies because muscle AcP is a small, simple protein of only 98 amino acids consisting of a five-stranded antiparallel  $\beta$ -sheet and two parallel  $\alpha$ -helices. Mutations in the muscle AcP between residues 16-31 and 87-98, which includes its phosphate binding site at Arg-23, significantly increases the rate of aggregation. These mutations correlate with changes in the hydrophobicity of AcP and a conversion of the  $\alpha$ -helical structures to  $\beta$ -sheets. Therefore, a reduction in the net charge of a protein may be a key determinant in some forms of protein deposition diseases.

## REFERENCES

1. Serpell, L.C., et al. 1997. The molecular basis of amyloidosis. *Cell. Mol. Life Sci.* 53: 871-887.
2. Chiti, F., et al. 2000. Mutational analysis of the propensity for amyloid formation by a globular protein. *EMBO J.* 19: 1441-1449.
3. Chiti, F., et al. 2001. Reduction of the amyloidogenicity of a protein by specific binding of ligands to the native conformation. *Protein Sci.* 10: 879-886.
4. Taddei, N., et al. 2001. Folding and aggregation are selectively influenced by the conformational preferences of the  $\alpha$ -helices of muscle acylphosphatase. *J. Biol. Chem.* 276: 37149-37154.
5. Chiti, F., et al. 2002. Studies of the aggregation of mutant proteins *in vitro* provide insights into the genetics of amyloid diseases. *Proc. Natl. Acad. Sci. USA* 99: 16419-16426.

## CHROMOSOMAL LOCATION

Genetic locus: ACYP2 (human) mapping to 2p16.2; Acyp2 (mouse) mapping to 11 A4.

## SOURCE

ACYP2 (B-3) is a mouse monoclonal antibody raised against amino acids 1-99 representing full length ACYP2 of human origin.

## PRODUCT

Each vial contains 200  $\mu$ g IgG<sub>2b</sub> kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

ACYP2 (B-3) is available conjugated to agarose (sc-398298 AC), 500  $\mu$ g/0.25 ml agarose in 1 ml, for IP; to HRP (sc-398298 HRP), 200  $\mu$ g/ml, for WB, IHC(P) and ELISA; to either phycoerythrin (sc-398298 PE), fluorescein (sc-398298 FITC), Alexa Fluor<sup>®</sup> 488 (sc-398298 AF488), Alexa Fluor<sup>®</sup> 546 (sc-398298 AF546), Alexa Fluor<sup>®</sup> 594 (sc-398298 AF594) or Alexa Fluor<sup>®</sup> 647 (sc-398298 AF647), 200  $\mu$ g/ml, for WB (RGB), IF, IHC(P) and FCM; and to either Alexa Fluor<sup>®</sup> 680 (sc-398298 AF680) or Alexa Fluor<sup>®</sup> 790 (sc-398298 AF790), 200  $\mu$ g/ml, for Near-Infrared (NIR) WB, IF and FCM.

## APPLICATIONS

ACYP2 (B-3) is recommended for detection of muscle ACYP2 of mouse, rat and human origin by Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), immunoprecipitation [1-2  $\mu$ g per 100-500  $\mu$ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for ACYP2 siRNA (h): sc-38900, ACYP2 siRNA (m): sc-38901, ACYP2 shRNA Plasmid (h): sc-38900-SH, ACYP2 shRNA Plasmid (m): sc-38901-SH, ACYP2 shRNA (h) Lentiviral Particles: sc-38900-V and ACYP2 shRNA (m) Lentiviral Particles: sc-38901-V.


Molecular Weight of ACYP2: 11 kDa.

Positive Controls: human skeletal muscle extract: sc-363776 or rat skeletal muscle extract: sc-364810.

## RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgG $\kappa$  BP-HRP: sc-516102 or m-IgG $\kappa$  BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker<sup>™</sup> Molecular Weight Standards: sc-2035, UltraCruz<sup>®</sup> Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use m-IgG $\kappa$  BP-FITC: sc-516140 or m-IgG $\kappa$  BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz<sup>®</sup> Mounting Medium: sc-24941 or UltraCruz<sup>®</sup> Hard-set Mounting Medium: sc-359850.

## DATA



ACYP2 (B-3): sc-398298. Western blot analysis of ACYP2 expression in human skeletal muscle (A) and rat skeletal muscle (B) tissue extracts.

## STORAGE

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.

Alexa Fluor<sup>®</sup> is a trademark of Molecular Probes, Inc., Oregon, USA